Sandoz Tries Again With US Pegfilgrastim

Sandoz has resubmitted its application for biosimilar pegfilgrastim to the FDA, having been knocked back with a complete response letter in 2016.

TryAgain
Sandoz Is Making Another Attempt With Its US Pegfilgrastim Biosimilar • Source: Shutterstock

Sandoz has refiled its application for biosimilar pegfilgrastim with the US Food and Drug Administration (FDA), nearly three years after the firm was knocked back by a complete response letter (CRL) in June 2016 for its initial application.

Having originally planned to refile the application for its LA-EP2006 biosimilar version of Amgen’s Neulasta in late 2018, Sandoz in...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.